Insider Filing: Pontifax-Linked Director Converts Preferred, Purchases 1M LBRX Shares
Rhea-AI Filing Summary
Ran Nussbaum, a director associated with Pontifax entities, reported acquisitions of LB Pharmaceuticals (LBRX) securities on 09/12/2025. The filing shows an automatic conversion of Series C redeemable convertible preferred stock into common stock and a purchase of common shares. Specifically, 10,000,000 shares of Series C preferred were converted immediately prior to the companys IPO closing, and 1,000,000 common shares were acquired at $15.00 per share. After these transactions, the reporting person (through Pontifax-related entities) beneficially owned 1,411,681 common shares, held indirectly. The filing identifies Pontifax (Israel) VI LP and Pontifax (Cayman) VI LP as holders of the underlying securities and notes shared voting and investment power through Pontifax management.
Positive
- Conversion of 10,000,000 Series C preferred into common increases common equity available post-IPO
- Acquisition of 1,000,000 common shares at $15.00 provides a clear transaction price and shows continued investor participation
- Beneficial ownership disclosure totals 1,411,681 common shares held indirectly, enhancing transparency
Negative
- None.
Insights
TL;DR: Director-associated investor converted large preferred position and purchased 1,000,000 shares at $15, increasing indirect common ownership to 1,411,681 shares.
The Form 4 documents two material non-derivative transactions: an automatic conversion of 10,000,000 Series C preferred shares into common stock immediately prior to the IPO closing, and a purchase of 1,000,000 common shares at $15.00 each on 09/12/2025. The resulting reported beneficial ownership attributable to Pontifax entities totals 1,411,681 common shares held indirectly. From a capital-structure viewpoint, the conversion extinguishes preferred claims and increases the public float of common shares; the disclosed purchase at a stated $15 price establishes a concrete valuation point for that block of shares on the transaction date.
TL;DR: Reporting shows Pontifax entities exercise of conversion rights and additional buy reflects continued economic exposure and shared voting power via management GP.
The filing clarifies that Pontifax (Israel) VI LP and Pontifax (Cayman) VI LP hold the shares and convertible preferred, with Pontifax VI G.P. and Pontifax Management IV G.P. as general partners. Messrs. Tomer Kariv and Ran Nussbaum are identified as Managing Partners of Pontifax Management, and may be deemed to share voting and investment power. The Form 4 is consistent with required disclosure of indirect ownership and confirms the shift from preferred to common equity for a significant block of securities.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series C Preferred Stock | 10,000,000 | $0.00 | -- |
| Conversion | Common Stock | 411,681 | $0.00 | -- |
| Purchase | Common Stock | 1,000,000 | $15.00 | $15.00M |
Footnotes (1)
- Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering. Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.